Zollinger-Ellison syndrome

Netazepide

Netazepide is a gastrin/cholecystokinin (CCK)-2 receptor antagonist that is currently being investigated as a potential treatment for the type of gastric carcinoids that develop in patients with atrophic gastritis, and for gastric carcinoids associated with the presence of multiple endocrine neoplasia type 1 (MEN1) and ZES.[88]Moore AR, Boyce M, Steele IA, et al. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One. 2013 Oct 1;8(10):e76462. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788129 http://www.ncbi.nlm.nih.gov/pubmed/24098507?tool=bestpractice.com